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but down-regulated in LNCaP cells.
Sequencing of the AR binding region iden-
tified a MNLP (rs38668493) where a
47 bp sequence is replaced by a novel
21 bp sequence. The DuCaP cells have an
intact AR binding site (47 bp/47 bp)
whereas the LNCaP cells have deleted AR
binding site (21 bp/21 bp) which may
explain this discrepancy.
Conclusion: The unique MNLP genotype
upstream of IRX4 appears to regulate AR
binding, and directs the androgen-medi-
ated regulation of IRX4. Functional studies
using reporter gene assay for the MNLP
genotype may provide further insights for
the regulation of IRX4 expression in PCa.
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Objective: Understanding mechanisms
associated with the emergence of castration
resistant prostate cancer cells (CRPC) after
androgen deprivation therapy (ADT) is
essential to create new therapeutic agents
to counteract this aggressive form of pros-
tate cancer (PCa). Because proteases are
involved in almost all cancer associated
mechanisms such as cell proliferation,
invasion and metastasis, we are interested
in their modulation in PCa after ADT and
their involvement in CRPC.
Method: First, we screened for protease
expression in hormone sensitive prostate
cancer cells (LNCaP) after ADT and anti-
androgen treatments using a custom PCa
microarray. Secondly, using RT-qPCR and
western-blots, we confirmed the deregula-
tion of several proteases which are
repressed by androgen but induced after
ADT. Finally, we analysed their expression
in C4-2B cells, which are LNCaP derived
CRPC, and in Oncomine databases.
Results: We identified several proteases
overexpressed in LNCaP cells after ADT
which are already proposed as involved in
the aggressiveness of PCa or other cancers:
BMP1, TLL1 and TLL2, three proteases of
the astacin family; MMP16, a membrane
bound MMP; and KLK14, a protease of
the same family as PSA. We also showed
that several of these proteases are over-
expressed in C4-2B cells compared to
LNCaP cells and in Oncomine databases.
Conclusion: Androgen deprivation and
androgen targeted therapies in PCa is con-
ducive to the deregulation of protease gene
expression with the overexpression of sev-
eral proteases known to be associated with
aggressiveness of PCa or other cancers. In
vitro and in vivo confirmation of their role
in the androgen deprived environment as
seen with ADT will determine their poten-
tial utilisation as therapeutic targets for
CRPC.
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The androgen receptor (AR) is the main
therapeutic target for advanced prostate
cancer (PCa). Current treatments have
focused on inhibiting the transcriptional
activity of the AR, however androgens can
also induce non-genomic effects by facili-
tating the initiation of kinase signaling
cascades in PCa. Cells, including PCa,
secrete extracellular vesicles (EV), which
are able to mediate communication
between cells and can also contribute
towards these processes.
Objective: We investigated the effect of
androgens and androgen deprivation in
regulating EV secretion and the role of EV
in mediating paracrine signalling in AR+
PCa cells.
Methods: PCa cells were grown in char-
coal stripped serum and treated with
androgen dihydrotestosterone (DHT) or
antagonist MDV3100 (Enzalutamide). EV
was isolated from conditioned medium
using differential ultracentrifugation
method, analysed by electron microscopy
(morphology), qNANO (size) and protein
content (LCMS/MS), followed by bioinfor-
matic (R) and pathway analysis (Ingenuity).
Data was compared with microarray tran-
scriptome wide analysis to investigate the
contribution of AR. Functional analysis by
treating androgen deprived LNCaPs with
CD9-enriched EV and the effect of knock
down CD9 on cellular growth was observed
using life imaging system Incucyte.
Results: We found that androgen depriva-
tion increases the secretion of EV in AR+
PCa cells. However, DHT increases the
secretion of CD9-enriched EV, even
though androgen treatment does not alter
the mRNA level of CD9. The CD9-
enriched EVs were able to increase the
growth rate of androgen-deprived LNCaPs,
while siCD9 reduced cell growth. Andro-
gen manipulations minimally influenced
the EV content, suggesting that androgens
alter the EV pathway(s) discrete from
genomic AR action to mediate cellular
proliferation in LNCaPs.
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Objective: Prostate cancer (PCa) fre-
quently relapses after hormone ablation
therapy. Unfortunately, once progressed to
the castration resistant stage, the disease is
regarded as incurable as prostate tumours
are highly resistant to conventional chemo-
therapy. Therefore, an effective treatment
strategy is urgently needed for improving
the treatment outcome of the patients.
Method: We recently reported that the
two natural compounds polysaccharopep-
tide (PSP) and Gamma-tocotrienols (c-T3)
possessed potent anti-cancer activities
through targeting of CSCs. In the present
study, using both prostate cancer cell line
and xenograft models, we seek to
investigate the therapeutic potential of
combining c-T3 and PSP in the treatment
of prostate cancer.
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